Compare AbCellera Biologics Inc (ABCL) vs Redwire Corporation (RDW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Redwire Corporation — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Redwire Corporation trades at $10.38 (market cap $2.03B). The key difference: AbCellera Biologics Inc is the larger of the two by market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Redwire Corporation nearer its low. Which is the better fit depends on your goals.
| ABCL | RDW | |
|---|---|---|
Market Cap | $2.35B | $2.03B |
Sector | Health | Technology |
52-Week High | $8.12 | $25.90 |
52-Week Low | $2.78 | $5.06 |
Enterprise Value | $1.99B | $2.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
RDW trades at $11.36, up 0.44% on the day, amid a bearish technical trend and weak fundamentals. The company reported a net loss of $226.55M in 2025 with a -80.9% net income margin, though revenue grew to $335.38M. Recent news highlights volatility driven by SpaceX's IPO impact and a new defense contract, while analyst consensus remains bullish with an $19.00 price target.
The outlook is challenged by persistent losses and cash burn, but strong analyst buy ratings and contract wins offer potential upside. Key risks include dilution from equity offerings, intense space sector competition, and reliance on financing to fund operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
